MedTrace Logo

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

NCT03025477 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2021-02-11

No results posted yet for this study

Summary

CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.

Conditions

  • Ovarian Cancer, Epithelial

Interventions

DRUG

CC0 - Carboplatin (IV) - Paclitaxel (IV)

(6 cycles)

DRUG

CC0 - Cisplatin (IP) - Epirubicin (IV)

(6 cycles)

DRUG

CC>0 - Carboplatin (IV)- Paclitaxel (IV)

* carboplatin (IV) - paclitaxel (IV) (3 cycles) * Interval surgery * Carboplatin (IV) - paclitaxel (IV) (3 cycles)

DRUG

CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)

* Cisplatin (IV) - Epirubicin (IV) (3 cycles) * Interval surgery : * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles) * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)

Sponsors & Collaborators

  • GERCOR - Multidisciplinary Oncology Cooperative Group

    collaborator OTHER

  • Groupe Hospitalier Diaconesses Croix Saint-Simon

    lead OTHER

Principal Investigators

  • Richard VILLET, MD · Groupe Hospitalier Diaconessess Croix Saint Simon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2021-10-31
Completion
2032-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03025477 on ClinicalTrials.gov